S123 Pancreatic Injury Underlies Asymptomatic Lipase Elevation Induced by Immune Checkpoint Inhibitors

Introduction: Marked lipase elevations, often asymptomatic, occur due to immune checkpoint inhibitor (ICI) therapy. Asymptomatic lipase elevation (ALE) is managed differently than cases meeting criteria for pancreatitis. In ICI-treated patients we sought evidence of pancreatic injury on computed tomography scan (CT), positron emission tomography scan (PET), and through pancreas volumetry (volume increase at lipase elevation and loss on follow-up). Methods: We assembled a retrospective cohort of 1,146 ICI-treated patients who had a PET/CT within 1 month of peak serum lipase. We correlated PET and CT positivity with lipase levels. In a subset of 52 patients with lipase >3× the upper limit of normal (ULN), we performed serial pancreas volumetry on CT scans obtained before, at, and within 1 year of peak lipase elevation (LE). Results: PET positivity was rarely seen in those with lipase levels <3× ULN (1.02%) vs those with lipase >3× ULN (37.68%). In the volumetry cohort, 41/52 (80%) patients were asymptomatic; 25 (48%) were PET+, and 16 (31%) were CT+. We observed no increase in pancreatic volume at peak LE in any group (P = 0.4). However, substantial pancreatic volume loss developed within a year. Mean volume ± SD before and after peak LE in PET+/CT+ (n = 16), PET+/CT- (n = 9), and asymptomatic PET-/CT- (n = 27) patients was 76.3 ± 13 vs 45.8 ± 18 (P = 0.0014), 58.3 ± 14 vs 41.1 ± 17 (P = 0.0012), and 81.9 ± 7 vs 63.9 ± 10 (P = 0.0002), respectively. Among patients with lipase >3× ULN, >15% volume loss was seen in 72.4%, PET-positivity in 43.1% and CT-positivity in 27.6%. In asymptomatic lipase elevation (n = 41) 73% had >15% volume loss (before vs after: 77.6 ± 6 vs 55.9 ± 8, P = 4.28E-07). Conclusion: Asymptomatic lipase elevation after ICI treatment indicates pancreatic injury, despite not meeting criteria for pancreatitis. In those with >3× ULN lipase elevations, vast majority lose pancreatic volume on follow-up, though only a minority have changes on CT or PET. Mechanism of ICI-induced pancreatic injury needs further study.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001126952.50927.9b
Primary Topic
Diabetes and associated disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S123 Pancreatic Injury Underlies Asymptomatic Lipase Elevation Induced by Immune Checkpoint Inhibitors

Abdullah S. Shaikh, Suresh Chari, H.R. Chaudhry
The American Journal of Gastroenterology
Diabetes and associated disorders
article

S123 Pancreatic Injury Underlies Asymptomatic Lipase Elevation Induced by Immune Checkpoint Inhibitors

Abdullah S. Shaikh, Suresh Chari, H.R. Chaudhry
article en

Abstract

Introduction: Marked lipase elevations, often asymptomatic, occur due to immune checkpoint inhibitor (ICI) therapy. Asymptomatic lipase elevation (ALE) is managed differently than cases meeting criteria for pancreatitis. In ICI-treated patients we sought evidence of pancreatic injury on computed tomography scan (CT), positron emission tomography scan (PET), and through pancreas volumetry (volume increase at lipase elevation and loss on follow-up). Methods: We assembled a retrospective cohort of 1,146 ICI-treated patients who had a PET/CT within 1 month of peak serum lipase. We correlated PET and CT positivity with lipase levels. In a subset of 52 patients with lipase >3× the upper limit of normal (ULN), we performed serial pancreas volumetry on CT scans obtained before, at, and within 1 year of peak lipase elevation (LE). Results: PET positivity was rarely seen in those with lipase levels <3× ULN (1.02%) vs those with lipase >3× ULN (37.68%). In the volumetry cohort, 41/52 (80%) patients were asymptomatic; 25 (48%) were PET+, and 16 (31%) were CT+. We observed no increase in pancreatic volume at peak LE in any group (P = 0.4). However, substantial pancreatic volume loss developed within a year. Mean volume ± SD before and after peak LE in PET+/CT+ (n = 16), PET+/CT- (n = 9), and asymptomatic PET-/CT- (n = 27) patients was 76.3 ± 13 vs 45.8 ± 18 (P = 0.0014), 58.3 ± 14 vs 41.1 ± 17 (P = 0.0012), and 81.9 ± 7 vs 63.9 ± 10 (P = 0.0002), respectively. Among patients with lipase >3× ULN, >15% volume loss was seen in 72.4%, PET-positivity in 43.1% and CT-positivity in 27.6%. In asymptomatic lipase elevation (n = 41) 73% had >15% volume loss (before vs after: 77.6 ± 6 vs 55.9 ± 8, P = 4.28E-07). Conclusion: Asymptomatic lipase elevation after ICI treatment indicates pancreatic injury, despite not meeting criteria for pancreatitis. In those with >3× ULN lipase elevations, vast majority lose pancreatic volume on follow-up, though only a minority have changes on CT or PET. Mechanism of ICI-induced pancreatic injury needs further study.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 67%
Diabetes and associated disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

S123 Pancreatic Injury Underlies Asymptomatic Lipase Elevation Induced by Immune Checkpoint Inhibitors — Abdullah S. Shaikh, Suresh Chari, et al. · The American Journal of Gastroenterology (2025) | TGRS Research Map | TGRS